Compare Organon & Co. Common Stock (OGN) vs Roku Inc. Class A Common Stock (ROKU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Roku Inc. Class A Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Roku Inc. Class A Common Stock trades at $152.43 (market cap $22.67B). The key difference: Roku Inc. Class A Common Stock is far larger — about 6.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Roku Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Roku Inc. Class A Common Stock for 6 Days on average.
| OGN | ROKU | |
|---|---|---|
Market Cap | $3.62B | $22.67B |
Volume | 2,892,999 | 1,039,228 |
Sector | Health | Media |
52-Week High | $13.81 | $159.76 |
52-Week Low | $5.70 | $82.93 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $20.59B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Roku trades at $152.66, down slightly by 0.1% today. The stock shows mixed technical signals with a neutral overall rating. Fundamentally, revenue growth is solid with 2026 projections at $5.2B, while profitability improved significantly with net income margin rising to 6.81%. Recent earnings beats and the pending Fox acquisition approval highlight positive momentum. Analyst consensus is evenly split between Buy and Hold with a $161.38 price target.
Outlook remains cautiously optimistic with strong earnings performance and acquisition synergies offering upside potential. Key risks include regulatory scrutiny of the Fox deal, competitive pressures in streaming, and negative cash flow trends. The stock presents a growth opportunity if execution continues, but investors should monitor acquisition progress and profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Roku Inc. Class A Common Stock
Roku operates a streaming platform that combines its operating system, streaming devices, TV partnerships, and advertising services. It connects viewers with streaming content and services.
Read more on ROKU →
